Novel FVIIIa-mimetic molecule with the potential to be the first oral treatment for severe hemophilia A


Jacob Lund, Ph.D.
Novo Nordisk A/S
Bagsvaerd, Denmark

Weekly to monthly dosing frequency of FVIIIa-mimetic approach has enabled subcutaneous prophylactic treatment, thus reducing the burden on patients with hemophilia. An orally available option may eliminate the need for injections. Jacob Lund, Ph.D., discusses the aim of their teams to develop the first ever oral FVIIIa-mimetic treatment for hemophilia A. This presentation discusses the orally bioavailable novel agent Inno8, which is a small FVIIIa-mimetic bidomain antibody with ultrahigh potency, a long plasma half-life and oral absorption demonstrating potential as the first ever oral treatment of severe HA.

Previous Article Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in people with haemophilia A
Next Article Thrombosis survivor Robyne Toseland shares her story: “It felt as though an elephant was sitting on my chest”